Milestone demonstrates how internet communities can drive real change: funding prevention, supporting wellness, and proving that collective action mattersYucca Valley,...
- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective...
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors...
MINNEAPOLIS, June 12, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on...
BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies,...
Echo IQ's AI platform to be evaluated in collaboration with Mayo Clinic for assessing cardiac risk in patients receiving cancer...
LOUISVILLE, Ky., June 12, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “the Company”) (NASDAQ: BTSG), a leading provider...
-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of...
PALO ALTO, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative...
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain...
Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2...
Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and...
— Growing body of ORLADEYO® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization...
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable safety profile...
COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its...
Leading allergy experts to convene in Istanbul to explore how science, prevention and policy can reduce the global impact of...
— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —The ESLIM-02 study underscores sovleplenib’s potential to...
DALLAS, June 11, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products,...
New York, NY, June 11, 2026 (GLOBE NEWSWIRE) -- Leaping Straight to Neurotoxin Treatments like Botox and Dysport, NextGen Medical...
Cover Image Eliaz Therapeutics Launches Reg CF Raise to Advance First Device Targeting Sepsis Santa Rosa, CA, USA, June 11,...